References
- Asai K, Hirabayashi T, Houjou T, Uozumi N, Taguchi R, Shimizu T. (2003). Human group IVC phospholipase A2 (cPLA2gamma). Roles in the membrane remodeling and activation induced by oxidative stress. J Biol Chem 278:8809–8814.
- Barnes PJ. (2000). Chronic obstructive pulmonary disease. N Engl J Med 343:269–280.
- Barnes PJ. (2010). New therapies for chronic obstructive pulmonary disease. Med Princ Pract 19:330–338.
- Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, Holz O, Buhl R, Magnussen H, Jörres RA. (2008). Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 21:409–417.
- Hara K, Yamashita S, Fujisawa A, Ishiwa S, Ogawa T, Yamamoto Y. (1999). Oxidative stress in newborn infants with and without asphyxia as measured by plasma antioxidants and free fatty acids. Biochem Biophys Res Commun 257:244–248.
- Hicks A, Goodnow R Jr, Cavallo G, Tannu SA, Ventre JD, Lavelle D, Lora JM, Satjawatcharaphong J, Brovarney M, Dabbagh K, Tare NS, Oh H, Lamb M, Sidduri A, Dominique R, Qiao Q, Lou JP, Gillespie P, Fotouhi N, Kowalczyk A, Kurylko G, Hamid R, Wright MB, Pamidimukkala A, Egan T, Gubler U, Hoffman AF, Wei X, Li YL, O’Neil J, Marcano R, Pozzani K, Molinaro T, Santiago J, Singer L, Hargaden M, Moore D, Catala AR, Chao LC, Benson J, March T, Venkat R, Mancebo H, Renzetti LM. (2010). Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates. Prostaglandins Other Lipid Mediat 92:33–43.
- Japanese Respiratory Society. (2009). Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Nihon Kokyuki Gakkai Zasshi. Suppl: 1–137. [Japanese]
- Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. (2003). Exhaled leukotrienes and prostaglandins in COPD. Thorax 58:585–588.
- National institute of healthy, National Heart, Lung and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease. (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases. Publication Number 2701, 2001.
- Pawliczak R, Huang XL, Nanavaty UB, Lawrence M, Madara P, Shelhamer JH. (2002). Oxidative stress induces arachidonate release from human lung cells through the epithelial growth factor receptor pathway. Am J Respir Cell Mol Biol 27:722–731.
- Praticò D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. (1998). Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 158:1709–1714.
- Wada H, Goto H, Saitoh E, Ieki R, Okamura T, Ota T, Hagiwara S, Kodaka T, Yamamoto Y. (2005). Reduction in plasma free fatty acid in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 15: 465.
- Wada H, Hagiwara S, Saitoh E, Ieki R, Okamura T, Ota T, Iguchi M, Yuasa K, Kodaka T, Koishi T, Yamamoto Y, Goto H. (2006). Increased oxidative stress in patients with chronic obstructive pulmonary disease (COPD) as measured by redox status of plasma coenzyme Q10. Pathophysiology 13:29–33.
- Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Harnden SM, Kim V, Marchetti N, Martinez FJ, McEvoy CE, Niewoehner DE, Reilly JJ, Rice K, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Lazarus SC; COPD Clinical Research Network. (2011). Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD 8:21–29.